Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft corrections and versioning policy

Consultation on the policy governing how the Institute corrects a published document and how versions are numbered, retained and linked. The draft retains every superseded version at a stable address and requires that a correction state what the document…

Document identifier
CEI-CP-022
Series
Public comment period
Version
1.0
Published
06 Sep 2024
Last reviewed
06 Sep 2024
Next review
06 Sep 2025
Identifier
10.71829/cei.cp.22
Certainty
Not rated
Cycle
2024 Q3
Window
16 Jul 2024 – 13 Aug 2024
Status
Closed
Submissions
19

§1Consultation and window

§1.1Window

Opened
16 July 2024
Closed
13 August 2024
Duration
28 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
19

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Should a superseded version remain retrievable at its own address, or should it be replaced with a notice?
  2. Is the threshold between a correction and a new version drawn in the right place?
  3. Should a correction state the previous wording, or is a description of the change sufficient?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. Superseded versions remain retrievable, and a correction states the previous wording in full, which respondents argued was the only form of correction a reader can check.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.